In the KEYNOTE-010 study, the magnitude of benefit with pembrolizumab was associated with the levels of PD-L1 expression, with increased survival benefits in patients with PD-L1 expression ≥  50% of tumor cells (regardless of the staining intensity with the 22C3 clone) [14]. The gene discussed is CD274; the disease is neoplasm.